Answers are grounded in this paper and cite their sources.
Type 1 diabetes (T1D) is an autoimmune disease mediated by autoreactive T cells. Current treatments primarily target symptom control and struggle to fundamentally regulate the abnormal immune response. Therefore, developing novel biotherapeutic strategies that combine immunomodulation and tissue protection is crucial. Recent studies have shown that alpha-1 antitrypsin (AAT) can delay or even reverse disease progression in non-obese diabetic mice and improve transplanted islet survival, demonstrating its potential for treating autoimmune diseases. This article systematically reviews the gene structure, biological function, and the impact of N-glycosylation on the activity of AAT. It focuses on analyzing the production advantages of CHO cell-derived recombinant AAT (rAAT) and key technologies such as ion exchange chromatography, affinity chromatography, and continuous purification. The study demonstrates that CHO cells can achieve glycosylation modifications close to those of natural AAT, and a multi-step chromatographic strategy can yield high-purity, high-activity rAAT products. In the future, the purification process should be further optimized, the functional evaluation system should be improved, and its therapeutic value in T1D and other autoimmune diseases should be verified through clinical research, so as to provide a theoretical basis for the development of novel immunomodulatory biological agents.
No takes yet. Share an insight, caveat, or question.
Yuqi Sun (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: